Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
People With MS Face Higher Rates of Harassment, Criticism at Work Than Healthy Employees
Patients with multiple sclerosis (MS) reported higher rates of harassment and criticism in the workplace than their healthy counterparts, even after informing employers and coworkers about their diagnosis.
Study: Muscle Loss May Lead to Higher Mortality and Costs for Patients Hospitalized for COPD
A new study has found that muscle loss can lead to increased rates of mortality and morbidity in patients with chronic obstructive pulmonary disease (COPD). However, one expert remains skeptical whether the study represents the full scope of patients at risk.
Supplemental Process Can Aid in Assessing Value of Rare Disease Treatments
A study looking at the ways in which different countries handle appraisal and reimbursement processes for rare disease treatments (RDTs) revealed that implementing supplemental processes can aid in patient and physician decision making.
Social Media May Benefit Patients With MS-Associated Depression
By delivering helpful information and fostering online communities, social media may provide rehabilitation and psychological benefits for patients with multiple sclerosis (MS) who have depression, according to the results of a recent Iranian study.
Gaps Remain Between European Regions for Hemophilia Care Despite Improvements
Hemophilia care principles have been on the rise in Europe over the course of the last decade, however, differing regions and policies on the continent reveal gaps in access to various treatments and specialty services.
Review Calls For Clear Guidance to Ensure Patient Centricity in Orphan Drug Trials
Researchers called for new guidance to address the underreporting of patient engagement in rare disease clinical trials after finding a dismal amount of patient-reported outcome measures listed in orphan drug labeling claims.